459 related articles for article (PubMed ID: 17063350)
41. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
42. Non-invasive molecular detection of bladder cancer recurrence.
Amira N; Mourah S; Rozet F; Teillac P; Fiet J; Aubin P; Cortesse A; Desgrandchamps F; Le Duc A; Cussenot O; Soliman H
Int J Cancer; 2002 Sep; 101(3):293-7. PubMed ID: 12209982
[TBL] [Abstract][Full Text] [Related]
43. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
44. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
45. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
[TBL] [Abstract][Full Text] [Related]
46. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
47. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
Lotan Y; Roehrborn CG
J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
[TBL] [Abstract][Full Text] [Related]
49. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
50. [Diagnosis and treatment of urethral recurrence after radical cystectomy in the male].
Huguet J
Actas Urol Esp; 2012 Jan; 36(1):42-7. PubMed ID: 21821317
[TBL] [Abstract][Full Text] [Related]
51. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States.
Messing EM; Teot L; Korman H; Underhill E; Barker E; Stork B; Qian J; Bostwick DG
J Urol; 2005 Oct; 174(4 Pt 1):1238-41. PubMed ID: 16145377
[TBL] [Abstract][Full Text] [Related]
52. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
53. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
54. The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma.
Jayachandran S; Unni Mooppan MM; Wax SH; Kim H
J Urol; 1984 Jul; 132(1):21-3. PubMed ID: 6726955
[TBL] [Abstract][Full Text] [Related]
55. Current Use and Promise of Urinary Markers for Urothelial Cancer.
Tabayoyong W; Kamat AM
Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
[TBL] [Abstract][Full Text] [Related]
56. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.
Picozzi S; Ricci C; Gaeta M; Ratti D; Macchi A; Casellato S; Bozzini G; Carmignani L
J Urol; 2012 Dec; 188(6):2046-54. PubMed ID: 23083867
[TBL] [Abstract][Full Text] [Related]
57. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
59. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
Leyh H; Mazeman E
Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
[TBL] [Abstract][Full Text] [Related]
60. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.
Raitanen MP; Kaasinen E; Lukkarinen O; Kauppinen R; Viitanen J; Liukkonen T; Tammela TL;
Urology; 2001 Apr; 57(4):680-4. PubMed ID: 11306380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
